Abu-Amara, T., Gebaly, Z. (2012). Effect of Sitagliptin "a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor" on the Endocrine Part of the Pancreas in Experimentally induced Diabetes in Adult Albino Rat; A Light Microscopic and Biochemical Studies. The Egyptian Journal of Hospital Medicine, 49(1), 933-945. doi: 10.21608/ejhm.2012.16228
Tamer M. M. Abu-Amara; Zeinab M. Gebaly. "Effect of Sitagliptin "a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor" on the Endocrine Part of the Pancreas in Experimentally induced Diabetes in Adult Albino Rat; A Light Microscopic and Biochemical Studies". The Egyptian Journal of Hospital Medicine, 49, 1, 2012, 933-945. doi: 10.21608/ejhm.2012.16228
Abu-Amara, T., Gebaly, Z. (2012). 'Effect of Sitagliptin "a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor" on the Endocrine Part of the Pancreas in Experimentally induced Diabetes in Adult Albino Rat; A Light Microscopic and Biochemical Studies', The Egyptian Journal of Hospital Medicine, 49(1), pp. 933-945. doi: 10.21608/ejhm.2012.16228
Abu-Amara, T., Gebaly, Z. Effect of Sitagliptin "a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor" on the Endocrine Part of the Pancreas in Experimentally induced Diabetes in Adult Albino Rat; A Light Microscopic and Biochemical Studies. The Egyptian Journal of Hospital Medicine, 2012; 49(1): 933-945. doi: 10.21608/ejhm.2012.16228
Effect of Sitagliptin "a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor" on the Endocrine Part of the Pancreas in Experimentally induced Diabetes in Adult Albino Rat; A Light Microscopic and Biochemical Studies
Sitagliptin is highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is considered as one of the new oral therapies for management of type II diabetes. Because of the sitagliptin unknown effects on the endocrine part of the pancreas, especially on the cellular levels, this study was done to evaluate its effect on the endocrine part of the pancreas in experimentally-induced type II diabetic in adult albino rats. Material and Methods: The present study was carried out on 30 adult male albino rats which were divided into; Group I (untreated control group), Group II (diabetic group), where type II diabetes had been induced via alloxan intake) and group III (treated group), where 0.14 mg/100 mg B.W. sitagliptin was given orally per day for 3 weeks after induction of type-2 diabetes.
The specimens were prepared for light microscopic examination. In parallel, the related biomedical parameters such as serum glucose and serum insulin levels had been estimated, statistically analyzed and compared between the three groups. Results: Sections of pancreas taken from diabetic rats showed morphological changes in islets of Langerhans cells in the form of pyknotic nuclei, cytoplasmic vacuolation, poor differentiation and abnormal shape and size of the cells. These morphological changes had been partially recovered in diabetic rats treated with sitagliptin. Also, the hyperglycemia and hypoinsulinemia that was detected in the control diabetic group had been nearly returned to normal after sitagliptin treatment. Conclusion: Sitagliptin drug has improved islet functions on both morphological and biomedical parameters in type II diabetic rats and can be taken into consideration as one of the new oral anti-diabetic drugs on the human level that need to be more investigated.
View on SCiNiTO
Top